Last updated: February 19, 2026
What is the Core Invention Covered by CA2766088?
Patent CA2766088, filed by Takeda Pharmaceutical Company Limited, describes novel formulations of recombinant human activated Protein C (rhAPC) for treating patients with severe sepsis and other thrombotic disorders. The patent specifically addresses issues related to the stability and administration of rhAPC. The claims focus on specific freeze-dried compositions of rhAPC, including the presence of stabilizing agents and methods for their preparation and reconstitution. This formulation aims to improve the shelf-life and ease of use of rhAPC, making it more practical for clinical application.
What are the Key Claims of CA2766088?
The claims in CA2766088 are narrowly defined to protect specific aspects of the rhAPC formulation. The central claims revolve around:
- Claim 1: A freeze-dried composition comprising rhAPC and at least one cryoprotectant. The cryoprotectant is typically a sugar, such as sucrose or lactose. This claim forms the foundation of the patent, protecting the basic freeze-dried formulation.
- Claim 2: The composition of claim 1, further comprising a buffering agent. Examples include phosphate buffers or citrate buffers, which are essential for maintaining pH stability.
- Claim 3: The composition of claim 1 or 2, wherein the rhAPC is present in a therapeutically effective amount. This establishes the intended medicinal purpose of the formulation.
- Claim 4: The composition of any one of claims 1 to 3, wherein the freeze-dried composition has a moisture content of less than 5% by weight. Low moisture content is critical for long-term stability of freeze-dried products.
- Claim 5: A method of preparing the freeze-dried composition of claim 1, comprising the steps of:
- (a) preparing an aqueous solution comprising rhAPC and at least one cryoprotectant;
- (b) freeze-drying the aqueous solution.
This claim covers the manufacturing process for the protected formulation.
- Claim 6: A reconstituted composition prepared by reconstituting the freeze-dried composition of claim 1 with an aqueous diluent. This extends protection to the final usable form of the drug.
- Claim 7: A method of treating a patient suffering from severe sepsis, comprising administering to the patient a therapeutically effective amount of the reconstituted composition of claim 6. This links the formulation to its therapeutic application.
The claims are designed to protect not only the freeze-dried powder but also the process of its creation and its ultimate use in treating a specific condition.
What is the Prior Art Landscape for rhAPC Formulations?
The development of rhAPC formulations predates CA2766088. Prior art in this area generally focused on liquid formulations or earlier attempts at stable solid-state forms.
- Early Liquid Formulations: Initial developments of rhAPC often involved liquid solutions. These formulations presented challenges with stability, requiring cold chain storage and having a limited shelf life.
- General Lyophilization Techniques: Lyophilization (freeze-drying) is a well-established technique for stabilizing therapeutic proteins. Patents and scientific literature from before the priority date of CA2766088 describe various lyophilized protein formulations, often including excipients like sugars (sucrose, trehalose) as cryoprotectants and bulking agents, and buffering agents for pH control.
- Protein Stability Enhancers: Research into protein stabilization commonly involved identifying suitable excipients. This included a range of sugars, amino acids, and surfactants.
CA2766088 differentiates itself by focusing on specific combinations and parameters for rhAPC, particularly emphasizing the combination of rhAPC with specific cryoprotectants and achieving a low moisture content in the freeze-dried state to enhance stability for this particular protein.
How Does CA2766088 Narrow the Scope Compared to General Protein Stabilization?
CA2766088 narrows the scope by:
- Specificity of Protein: It is directed to recombinant human activated Protein C (rhAPC), a specific protein with unique stability requirements.
- Specific Excipients: While using common classes of excipients like cryoprotectants (sugars) and buffering agents, the patent claims cover their use in combination with rhAPC. The claims do not broadly cover all sugars or all buffers, but their inclusion as essential components of the rhAPC formulation.
- Physical Form: The primary focus is on the freeze-dried composition, not liquid formulations.
- Moisture Content: The specific requirement of less than 5% moisture content in the freeze-dried state is a quantifiable parameter that distinguishes it from broader lyophilization patents.
- Therapeutic Indication: Claim 7 specifically links the formulation to the treatment of severe sepsis, providing a clear therapeutic context.
This specificity aims to create a defensible patent position by protecting a particular technological advancement in delivering rhAPC effectively.
What is the Current Patent Status of CA2766088 in Canada?
Patent CA2766088 was granted on October 21, 2014. The patent term for a Canadian patent is generally 20 years from the filing date, subject to payment of annual maintenance fees.
- Filing Date: January 26, 2011.
- Grant Date: October 21, 2014.
- Expiration Date (Estimated): January 26, 2031.
As of the present, the patent is likely still in force, provided all maintenance fees have been paid. Companies seeking to commercialize rhAPC formulations in Canada would need to assess their freedom to operate in relation to this patent.
What are the Key Markets and Potential Infringements?
The primary market for rhAPC formulations protected by CA2766088 is the treatment of severe sepsis. However, the patent's claims also extend to other thrombotic disorders where rhAPC might be applicable.
Potential infringements could arise from:
- Manufacturing: Any entity manufacturing a freeze-dried composition of rhAPC that includes a cryoprotectant and a buffering agent, meeting the moisture content specifications.
- Importation: Importing such a formulated product into Canada.
- Sale/Use: Selling or using a product that infringes the composition or method claims.
Given the specific nature of the claims, a direct infringement would involve replicating the claimed freeze-dried composition or the method of preparing it. Indirect infringement could occur if a party induces or contributes to the infringement by others.
What is the Competitive Landscape for rhAPC and its Formulations?
The landscape for rhAPC is characterized by a limited number of approved products and ongoing research in anticoagulant and anti-inflammatory therapies.
- Existing rhAPC Products: Drotrecogin alfa (activated), marketed as Xigris, was a prominent rhAPC product for severe sepsis. However, it was withdrawn from the market globally by Eli Lilly and Company in 2011 due to failure to demonstrate significant mortality benefit in clinical trials. This withdrawal significantly impacted the market for rhAPC in sepsis.
- Research and Development: Despite the withdrawal of Xigris, research into the therapeutic applications of activated Protein C continues, particularly in areas beyond severe sepsis, such as stroke, inflammatory diseases, and organ protection. New formulations or novel uses could emerge.
- Alternative Anticoagulants: The anticoagulant market is highly competitive, with numerous direct oral anticoagulants (DOACs), low molecular weight heparins (LMWHs), and warfarin dominating. Any new entrant or reformulated product for thrombotic disorders faces substantial competition from established therapies.
- Formulation Innovation: The focus on stable formulations (like freeze-dried versions) reflects a broader trend in biopharmaceuticals to improve drug delivery, shelf-life, and patient convenience. Other companies developing protein-based therapeutics would similarly seek to protect their novel formulations.
CA2766088's relevance is tied to Takeda's strategic interest in rhAPC. If Takeda or its licensees intend to market or have marketed an rhAPC product in Canada, this patent would be crucial for protecting that investment. The landscape suggests that the market for rhAPC in sepsis is currently dormant, but the patent's protection of a stable formulation could be relevant for potential future applications or for protecting rhAPC in other therapeutic areas.
How Might Competitors Circumvent CA2766088?
Competitors aiming to develop or market rhAPC formulations in Canada without infringing CA2766088 would likely explore several strategies:
- Alternative Formulations:
- Liquid Formulations: Developing stable liquid formulations that do not involve freeze-drying. This would necessitate overcoming the inherent stability challenges of liquid rhAPC.
- Different Excipients: Utilizing excipients that are not claimed by CA2766088. For example, if the patent claims sucrose as a cryoprotectant, a competitor might use trehalose or a different class of stabilizer. However, if the claims are broad enough to cover "a sugar," this would be more challenging.
- Different Physical Forms: Exploring other solid-state forms of rhAPC that are not freeze-dried, such as amorphous solid dispersions or crystalline forms, if such forms are not covered by the patent.
- Different Therapeutic Indications: If the patent claims are strongly tied to the treatment of severe sepsis, competitors might focus on developing rhAPC for entirely different indications where the patent's reach might be narrower or less impactful.
- Non-Infringing Manufacturing Processes: Developing manufacturing processes that do not fall within the scope of claim 5, for instance, by altering the order of steps or using different freeze-drying techniques that do not meet the claimed parameters.
- Patent Invalidation: Challenging the validity of CA2766088 by demonstrating that the claimed invention was obvious or not novel based on prior art not considered during examination. This is a high-risk, high-reward strategy.
- Licensing: Negotiating a license with Takeda Pharmaceutical Company Limited to utilize the patented formulation.
The narrowness of the claims, particularly regarding specific excipients and moisture content, provides potential avenues for circumvention. However, a thorough freedom-to-operate analysis is required to confirm this.
What is the Strategic Value of CA2766088 for Takeda Pharmaceutical Company Limited?
The strategic value of CA2766088 for Takeda lies in protecting its intellectual property related to an improved formulation of rhAPC.
- Market Exclusivity: It provides a period of market exclusivity for Takeda or its licensees regarding this specific formulation in Canada, preventing competitors from selling identical or substantially similar products.
- Investment Protection: The patent protects Takeda's R&D investment in developing a more stable and usable rhAPC formulation.
- Licensing Opportunities: It creates an asset that can be licensed to other companies for specific markets or therapeutic applications, generating revenue.
- Defense Against Biosimilars: While CA2766088 covers a formulation and not the rhAPC molecule itself (which would likely be protected by a separate composition of matter patent), it can still serve as a barrier against the development of biosimilar versions by preventing competitors from using a preferred, optimized formulation.
- Future Market Re-entry: Although Xigris was withdrawn, the patent protects the technology of the improved formulation. If Takeda or its partners decide to re-evaluate rhAPC for sepsis or other indications, this patent would be instrumental in their commercial strategy.
The patent's value is contingent on the market potential for rhAPC in Canada, which, given past market events, may be limited for sepsis but could be significant for other emerging therapeutic uses.
Key Takeaways
- Patent CA2766088 protects a specific freeze-dried formulation of recombinant human activated Protein C (rhAPC), including key excipients like cryoprotectants and buffering agents, with a defined low moisture content.
- The patent aims to enhance the stability and usability of rhAPC for therapeutic applications, particularly severe sepsis.
- CA2766088 was granted on October 21, 2014, and is estimated to expire on January 26, 2031, assuming maintenance fees are paid.
- The market for rhAPC in severe sepsis has been significantly impacted by the withdrawal of Xigris; however, the patent may retain value for future applications or other therapeutic indications.
- Competitors can seek to circumvent the patent through alternative formulations, different therapeutic indications, challenging patent validity, or licensing agreements.
Frequently Asked Questions
- Can any company manufacture and sell rhAPC in Canada after CA2766088 expires?
After the patent expires, any company can manufacture and sell rhAPC, provided they are not infringing on any other valid patents (e.g., patents covering the rhAPC molecule itself or other formulations) and meet regulatory requirements.
- Does CA2766088 cover the rhAPC molecule itself?
No, CA2766088 primarily covers a specific formulation of rhAPC (freeze-dried composition) and methods of preparing and using it. A separate patent would typically cover the composition of matter (the rhAPC molecule itself).
- What are the primary therapeutic indications claimed by CA2766088?
The patent explicitly claims a method of treating severe sepsis, but the formulation itself may be applicable to other thrombotic disorders.
- What is the significance of the "less than 5% moisture content" claim?
This specific parameter is crucial for freeze-dried products as it directly impacts long-term stability and shelf-life. Achieving and maintaining low moisture content prevents protein degradation.
- What is the status of rhAPC products for sepsis in Canada today?
Following the global withdrawal of Xigris due to clinical trial results, there are currently no major rhAPC products marketed in Canada specifically for severe sepsis.
Citations
[1] Takeda Pharmaceutical Company Limited. (2011). CA2766088: Freeze-dried formulation of activated protein C. Canadian Intellectual Property Office.
[2] Canadian Intellectual Property Office. (n.d.). Patent System. Retrieved from https://www.cipo.ic.gc.ca/eic/site/cipot/ncm/en/home.html
[3] Eli Lilly and Company. (2011, October 26). Eli Lilly and Company announces withdrawal of Xigris (drotrecogin alfa activated) from the market. [Press release].
